{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-108629","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.021757+00:00","generated_at":"2026-05-31T02:21:59.005302+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Assembly Biosciences reports positive interim Phase 1a results for ABI-5366 in recurrent genital herpes","bullets":["ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.","Half-life of approximately 20 days supports both once-weekly and once-monthly oral dosing schedules.","Screening for Phase 1b in participants with recurrent genital herpes is now underway.","Interim Phase 1b results are expected in the first half of 2025.","Single doses of ABI-5366 surpassed target plasma concentrations for antiviral efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-108629","json":"https://secwatch.observer/filing/0000950170-24-108629.json","markdown":"https://secwatch.observer/filing/0000950170-24-108629.md","text":"https://secwatch.observer/filing/0000950170-24-108629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/0000950170-24-108629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/asmb-20240923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:21:59.005302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}